TEL-AVIV, Israel, Feb 22 (GLOBE NEWSWIRE) -- RedHill
Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a
specialty biopharmaceutical company primarily focused on the development and
commercialization of late clinical-stage, proprietary, orally-administered,
small molecule drugs for gastrointestinal and inflammatory diseases and cancer,
today announced that the last patient enrolled in the Phase III study with
BEKINDA® 24 mg for the treatment of acute gastroenteritis and
gastritis (the GUARD study) has completed the treatment course and observation
period for the primary endpoint evaluation.
The randomized, double-blind, placebo-controlled Phase III GUARD
study with BEKINDA® 24 mg is being conducted in 29 U.S.
clinical sites and has treated 320 adults and children over the age of 12 with
gastroenteritis and gastritis. Top-line results are expected in the second
quarter of 2017.
Source : RedHill Biopharma Ltd.
No comments:
Post a Comment